IFN-γ suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins

被引:356
作者
Hu, Xiaoyu
Paik, Paul K.
Chen, Janice
Yarilina, Anna
Kockeritz, Lisa
Lu, Theresa T.
Woodgett, James R.
Ivashkiv, Lionel B. [1 ]
机构
[1] Cornell Univ, Weill Grad Sch Med Sci, Arthritis & Tissue Degenerat Program, Hosp Special Surg, New York, NY 10021 USA
[2] Cornell Univ, Weill Grad Sch Med Sci, Weill Med Coll, New York, NY 10021 USA
[3] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Immunol & Microbial Pathogenesis, New York, NY 10021 USA
[4] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada
关键词
D O I
10.1016/j.immuni.2006.02.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The control of IL-10 production and mechanisms that mediate synergy between IFN-gamma and TLR ligands are not well understood. We report that IFN-gamma augments induction of TNF alpha by TLR ligands, immune complexes, and zymosan by suppressing IL-10 production and thereby interrupting Stat3-mediated feedback inhibition. IFN-gamma altered TLR2-induced signal transduction by increasing GSK3 activity and suppressing MAPK activation, leading to diminished IL-10 production. Inhibition of GSK3 or ablation of the GSK3 beta gene ameliorated TLR2-induced peritonitis and arthritis. IFN-gamma suppressed the activity of CREB and AP-1, transcription factors that induce IL-10 expression and are regulated in part by MAPKs and GSK3. These results yield insight into mechanisms by which IFN-gamma regulates IL-10 production and TLR2-mediated inflammatory responses and identify inhibition of CREB and AP-1 as part of the macrophage response to IFN-gamma. GSK3 and CREB/AP-1 are key players in integrating IFN-gamma and TLR2 responses in innate immunity and inflammation.
引用
收藏
页码:563 / 574
页数:12
相关论文
共 65 条
  • [1] THE CELL BIOLOGY OF MACROPHAGE ACTIVATION
    ADAMS, DO
    HAMILTON, TA
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1984, 2 : 283 - 318
  • [2] Cutting edge: Different toll-like receptor agonists instruct dendritic cells to induce distinct th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-fos
    Agrawal, S
    Agrawal, A
    Doughty, B
    Gerwitz, A
    Blenis, J
    Van Dyke, T
    Pulendran, B
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (10) : 4984 - 4989
  • [3] Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways
    Ahmed, ST
    Ivashkiv, LB
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (09) : 5227 - 5237
  • [4] Toll-like receptor signalling
    Akira, S
    Takeda, K
    [J]. NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) : 499 - 511
  • [5] Toll-like receptor 2-mediated NF-κB activation requires a RacI-dependent pathway
    Arbibe, L
    Mira, JP
    Teusch, N
    Kline, L
    Guha, M
    Mackman, N
    Godowski, PJ
    Ulevitch, RJ
    Knaus, UG
    [J]. NATURE IMMUNOLOGY, 2000, 1 (06) : 533 - 540
  • [6] INTERLEUKIN-10 IS A CENTRAL REGULATOR OF THE RESPONSE TO LPS IN MURINE MODELS OF ENDOTOXIC-SHOCK AND THE SHWARTZMAN REACTION BUT NOT ENDOTOXIN TOLERANCE
    BERG, DJ
    KUHN, R
    RAJEWSKY, K
    MULLER, W
    MENON, S
    DAVIDSON, N
    GRUNIG, G
    RENNICK, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (05) : 2339 - 2347
  • [7] ACTIVATION OF PROTEIN-KINASE-C DECREASES PHOSPHORYLATION OF C-JUN AT SITES THAT NEGATIVELY REGULATE ITS DNA-BINDING ACTIVITY
    BOYLE, WJ
    SMEAL, T
    DEFIZE, LHK
    ANGEL, P
    WOODGETT, JR
    KARIN, M
    HUNTER, T
    [J]. CELL, 1991, 64 (03) : 573 - 584
  • [8] Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge
    Bullock, BP
    Habener, JF
    [J]. BIOCHEMISTRY, 1998, 37 (11) : 3795 - 3809
  • [9] Role of endogenous IL-10 in LPS-induced STAT3 activation and IL-1 receptor antagonist gene expression
    Carl, VS
    Gautam, JK
    Comeau, LD
    Smith, MF
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 76 (03) : 735 - 742
  • [10] GSK3 inhibitors: Development and therapeutic potential
    Cohen, P
    Goedert, M
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (06) : 479 - 487